Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Hepregen Launches First Dual-Species HepatoPac™ DMPK Assay Kits

Published: Wednesday, September 25, 2013
Last Updated: Tuesday, September 24, 2013
Bookmark and Share
Rat and human liver cells on a single tissue culture plate designed for high efficiency data collection.

Hepregen Corporation has announced the commercial launch of the Company's first application-oriented, dual-species HepatoPac™ kit designed specifically for use in metabolite identification and profiling.

Each kit contains one standard 24-well tissue culture plate, half containing micro-patterned human hepatocytes, and the other half containing micro-patterned rat hepatocytes (available in Wistar-Hahn or Sprague-Dawley strains).

The hepatocytes on these plates from both species remain fully functional for up to two months. These unique dual-species kits provide customers with a plug-in-ready product, designed for use in evaluating metabolite production in a discovery or development setting, or in any case where a quick comparative answer is beneficial.

Dr. Vincent Zurawski, Hepregen's chief executive officer stated, "The incredible flexibility of our HepatoPac™ assay systems allows Hepregen to provide customers with a variety of cost-effective options for generating predictive and mechanistic data regarding metabolite identification and profiling."

He added, "The launch of this new dual-species product represents another way in which Hepregen is responding to customer needs. Data collected from two species simultaneously in a single experiment, especially when one or just a few compounds need to be evaluated rapidly, provides the highest efficiency approach to predicting likely in vivo metabolic outcomes in the laboratory."

Jack McGeehan, Hepregen's vice president of operations, added, "Our new dual-species product is a perfect fit for both smaller pharmaceutical companies that are testing a limited number of compounds, or DMPK groups within larger companies who support program teams in need of quick answers to questions regarding likely best approaches to preclinical evaluation. Our new HepatoPac™ kit can provide answers that will support clinical trial design or approaches to toxicokinetic testing."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SOLVO Biotechnology and Hepregen Execute Co-Marketing Agreement
Agreement provides for European sales of Hepregen's HepatoPac® and HepatoMune™ proprietary products by SOLVO and provision of services using these products.
Wednesday, June 24, 2015
Scientific News
New Treatment for Pancreatic Cancer
Researchers at Purdue University have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
How Different People Respond To Aspirin
Study findings could be used to help identify those who would benefit most from aspirin use.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
A Metabolic Twist that Drives Cancer Survival
A novel metabolic pathway that helps cancer cells thrive in conditions that are lethal to normal cells has been identified.
Liver-On-Chip Tracks Dynamics of Cellular Function
Hebrew University’s liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.
Living Off the Fat of the Land
Do cancer cells synthesize the parts for new cells or scavenge them from the environment?
Liver Disease, Obesity Linked
Kanazawa University researchers find similarities in the impeded signalling between central insulin activity and glucose production in the liver for both obese mice and mice that have had the vagus nerve removed.
Decoding Ties Between Vascular Disease, Alzheimer’s
NIH consortium uses big data, team science to uncover complex interplay of factors.
Gene Identified that May Worsen Cancer Outcome
Some patients with breast cancer, lung cancer and leukaemia seem to fare poorly after treatment because of the effects of a particular gene, a new study finds.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!